在监狱中预审被拘留者中,随机比较延长释放与下语言布普伦诺芬的协议
Rebecca E Rottapel1, Thomas J Stopka1, Peter D Friedmann2
1Department of Public Health and Community Medicine, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02111, USA.
Addiction science & clinical practice
|October 28, 2025
概括
这项研究调查了长期释放的布普伦诺芬 (XRB) 监禁成年人与阿片类药物使用障碍 (OUD). 这些发现将指导高风险人群的治疗.
科学领域:
- 公共卫生 公共卫生
- 成 药物 药物 药物 药物
- 刑事司法 卫生 刑事司法 卫生
背景情况:
- 监狱中的成年人患上阿片类药物使用障碍 (OUD) 的比例很高,这为干预提供了关键的机会.
- 释放后过量服用的风险对于OUD离开监狱的人来说是相当大的.
- 对于OUD的审前被拘留者,早期诱导延长释放布伦诺芬 (XRB) 是一个关键的临床考虑因素.
研究的目的:
- 确定在有阿片类药物使用障碍 (OUD) 的审前被拘留者中启动延长释放布伦诺芬 (XRB) 的可行性和结果.
- 为治疗这种研究不足的高风险人群提供临床和政策指导方针.
主要方法:
- 一项为期3年的随机对照试验,涉及200名被监禁成年人OUD.
- 参与者被随机分配,在审判前的监禁期间接受延长释放布伦诺芬 (XRB) 或舌下布伦诺芬 (SLB).
- 评估的结果包括释放后的MOUD延续,布普伦诺芬转移,复发和死亡率.
主要成果:
- 该研究将评估监禁期间的XRB吸收.
- 关键指标包括参与者离开监狱的百分比与临床上活性剂量的布普伦诺啡.
- 释放后的结果,如MOUD的延续,转移,复发和死亡将被追踪90天.
结论:
- 这项研究将证明启动XRB的可行性和结果,用于OUD的审前被拘留者.
- 调查结果将为监狱环境中管理OUD的最佳实践和政策提供信息.
- 这项研究解决了理解OUD被监禁个人的治疗的关键差距.
相关概念视频
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
01:13Bioequivalence studies: Biowaivers
433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
260
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
260
01:30Modified-Release Drug Delivery Systems: Bioavailability
177
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
177
01:26Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319